Hyderabad, 30th September 2020: [Press Release] For the first time in the world, a device, developed by Sharp Corporation, equipped with Plasmacluster technology, which exposed an airborne novel coronavirus (SARS-CoV-2) to Plasmacluster ions for approximately 30 seconds, has effectively reduced the infectious titer of the virus by more than 90%. This achievement was accomplished in collaboration with Professor Jiro Yasuda of the National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University, Professor Asuka Nanbo (a board member of the Japanese Society for Virology) of the same institution, Professor Hironori Yoshiyama of the Department of Microbiology, Shimane University, Faculty of Medicine (also, a board member of the Japanese Society for Virology), and Nagasaki University, an internationally respected authority on infectious diseases research.
The outbreak of Coronavirus disease (COVID-19) caused by the novel coronavirus (SARS-CoV-2) was first reported in December 2019. By August 2020, this disease had already infected more than 25 million people and taken the lives of 840,000 individuals globally. This outbreak is an emergency faced by our society and made it necessary to take immediate countermeasures across a wide range of fields.
In 2004, Sharp demonstrated the effectiveness of Plasmacluster technology against feline (cat) coronavirus, a member of the Corona viridae family. In the following year of 2005, Sharp also demonstrated its effectiveness against the original SARS coronavirus (SARS- CoV), which caused the outbreak of 2002-2003 and is also genetically similar to the novel coronavirus (SARS-CoV-2). Now, Sharp has demonstrated its effectiveness against SARS-CoV-2 in airborne droplets.
On the day of the launch, Dr Jiro Yasuda, Professor of National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University said, “Disinfectants such as alcohol and detergents (surfactants) are well-known to be effective to reduce the risk of the virus on materials. However, for infection via aerosols (micro-droplets), there are few effective countermeasures such as a mask. Today, we demonstrated the effective inactivation of SARS-CoV-2 in airborne droplets by using Plasmacluster technology. We expect it would be useful to reduce the risk of infection in real spaces like offices, homes, medical facilities and vehicles too”.
Since 2000, Sharp has been demonstrating the effectiveness of Plasmacluster technology by working in collaboration with independent third-party research organizations around the world. So far, numerous independent research organizations have proven its clinical efficacy in suppressing the activity of harmful substances including new pandemic influenza viruses, drug-resistant bacteria, and mite allergens, as well as in reducing bronchial inflammation levels in children with asthma.
Plasmacluster and the Plasmacluster logos are registered trademarks of Sharp Corporation.
About Plasmacluster Technology-
Positively charged ions (H+ (H2O)m) and negatively charged ions (O2– (H2O)n) are released into the air simultaneously, and the positive and negative ions instantaneously bond on the surface of airborne bacteria, fungi, viruses, allergens, and the like, becoming OH (hydroxyl) radicals which have very high oxidizing power. This is a unique air purification technology that works to suppress the activity of bacteria, etc., by breaking down proteins on their surface by a chemical reaction.
Mechanism for Inhibiting the Activity of Airborne Bacteria
Comparison of Oxidizing Power
The OH– (hydroxyl) radical has the strongest oxidizing power among active oxygen species
Active Oxygen Species | Chemical Formula | Standard Oxidation Potential [V] |
OH– (hydroxyl) radical | OH | 2.81 |
Oxygen atom | O | 2.42 |
Ozone | O3 | 2.07 |
Hydrogen peroxide | H2O2 | 1.78 |
Hydroperoxyl radical | OOH | 1.70 |
Oxygen molecule | O2 | 1.23 |
■ Research Institutes That Provided Data for Sharp’s Academic Marketing
Target | Testing and Verification Organization |
Efficacy proven in clinical trials | Graduate School of Medicine, University of Tokyo / Public Health Research Foundation |
Faculty of Science and Engineering, Chuo University / Clinical Research Support Center, University Hospital, University of Tokyo | |
Animal Clinical Research Foundation | |
Soiken Inc. | |
School of Bioscience and Biotechnology, Tokyo University of Technology | |
National Trust Co., Ltd. / HARG Treatment Center | |
National Center of Tuberculosis and Lung Diseases, Georgia | |
Dentsu ScienceJam Inc. | |
Littlesoftware Inc. | |
National Institute of Fitness and Sports in Kanoya | |
Viruses | Kitasato Research Center of Environmental Sciences |
Seoul National University | |
Shanghai Municipal Center for Disease Control and Prevention, China | |
Kitasato Institute Medical Center Hospital | |
Retroscreen Virology, Ltd., UK | |
Shokukanken Inc. | |
University of Indonesia | |
Hanoi College of Technology, Vietnam National University, Vietnam | |
Institut Pasteur, Ho Chi Minh City, Vietnam | |
National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University | |
Allergens | Graduate School of Advanced Sciences of Matter, Hiroshima University |
Department of Biochemistry and Molecular Pathology, Graduate School of Medicine, Osaka City University | |
Fungi | Ishikawa Health Service Association |
University of Lübeck, Germany | |
Professor Gerhard Artmann, Aachen University of Applied Sciences, Germany | |
Japan Food Research Laboratories | |
Shokukanken Inc. | |
Shanghai Municipal Center for Disease Control and Prevention, China | |
Biostir Inc. | |
Medical Mycology Research Center, Chiba University | |
Bacteria | Ishikawa Health Service Association |
Shanghai Municipal Center for Disease Control and Prevention, China | |
Kitasato Research Center of Environmental Sciences | |
Kitasato Institute Medical Center Hospital | |
Dr. Melvin W. First, Professor Emeritus, Harvard School of Public Health, US | |
Animal Clinical Research Foundation | |
University of Lübeck, Germany | |
Professor Gerhard Artmann, Aachen University of Applied Sciences, Germany | |
Japan Food Research Laboratories | |
Shokukanken Inc. | |
Chest Disease Institute, Thailand | |
Biostir Inc. | |
Odors, pet smells | Boken Quality Evaluation Institute |
Skin beautifying effects | School of Bioscience and Biotechnology, Tokyo University of Technology |
Hair beautifying effects | Saticine Medical Co., Ltd. |
C.T.C Japan Ltd. | |
Plant | Facility of Agriculture, Shizuoka University |
Hazardous chemical substances | Sumika Chemical Analysis Service Ltd. |
Indian Institutes of Technology | |
Working mechanism of inhibitory effects on viruses, fungi, and bacteria | Professor Gerhard Artmann, Aachen University of Applied Sciences, Germany |
Working mechanism of inhibitory effects on allergens | Graduate School of Advanced Sciences of Matter, Hiroshima University |
Working mechanism of skin moisturizing (water molecule coating) effect | Research Institute of Electrical Communication, Tohoku University |